OncoCyte (NASDAQ:OCX – Get Rating) and Cardio Diagnostics (NASDAQ:CDIO – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.
Profitability
This table compares OncoCyte and Cardio Diagnostics' net margins, return on equity and return on assets.
Get
OncoCyte alerts:
| Net Margins | Return on Equity | Return on Assets |
| OncoCyte | -787.97% | -54.99% | -24.47% |
| Cardio Diagnostics | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of recent ratings for OncoCyte and Cardio Diagnostics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| OncoCyte | 0 | 3 | 1 | 0 | 2.25 |
| Cardio Diagnostics | 0 | 0 | 0 | 0 | N/A |
OncoCyte presently has a consensus target price of $1.35, indicating a potential upside of 193.48%. Cardio Diagnostics has a consensus target price of $8.00, indicating a potential upside of 614.29%. Given Cardio Diagnostics' higher possible upside, analysts plainly believe Cardio Diagnostics is more favorable than OncoCyte.
Valuation & Earnings
This table compares OncoCyte and Cardio Diagnostics' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| OncoCyte | $7.73 million | 7.06 | -$64.10 million | ($0.65) | -0.71 |
| Cardio Diagnostics | N/A | N/A | -$140,000.00 | N/A | N/A |
Cardio Diagnostics has lower revenue, but higher earnings than OncoCyte.
Institutional & Insider Ownership
81.2% of OncoCyte shares are owned by institutional investors. Comparatively, 77.3% of Cardio Diagnostics shares are owned by institutional investors. 4.1% of OncoCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Cardio Diagnostics beats OncoCyte on 5 of the 9 factors compared between the two stocks.
About OncoCyte
(Get Rating)
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
About Cardio Diagnostics
(Get Rating)
Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.
